Veru to Report Fiscal 2022 Second-Quarter Financial Results, Host Conference Call on May 12th
MIAMI, April 28, 2022 (GLOBE NEWSWIRE) — Veru Inc. (NASDAQ: VERU), a biopharmaceutical company, today…
News
Neuronetics to Report First Quarter 2022 Financial and Operating Results and Host Conference Call
MALVERN, Pa., April 28, 2022 (GLOBE NEWSWIRE) — Neuronetics, Inc. (NASDAQ: STIM), a commercial stage…
GBT Launches Inaugural Environmental, Social and Governance (ESG) Report
Report Highlights Efforts to Deliver Long-term Sustainable Value for Patients and Communities and Advance Diversity,…
CytomX Therapeutics to Report First Quarter 2022 Financial Results on May 5, 2022
SOUTH SAN FRANCISCO, Calif., April 28, 2022 (GLOBE NEWSWIRE) — CytomX Therapeutics, Inc. (Nasdaq: CTMX),…
Timber Pharmaceuticals Announces Fast Track Designation Granted by FDA for TMB-001 in Severe Subtypes of Congenital Ichthyosis
Company expects to launch pivotal Phase 3 ASCEND clinical trial to evaluate TMB-001 within the…
Caladrius Biosciences to Host First Quarter 2022 Financial Results Conference Call on Thursday, May 5, 2022, at 4:30 p.m. Eastern Time
BASKING RIDGE, N.J., April 28, 2022 (GLOBE NEWSWIRE) — Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius”…
Jounce Therapeutics to Announce First Quarter 2022 Financial Results and Host Conference Call on Thursday, May 5, 2022
CAMBRIDGE, Mass., April 28, 2022 (GLOBE NEWSWIRE) — Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage…
Motus GI to Release First Quarter Results and Provide a Business Update on May 12
FORT LAUDERDALE, Fla., April 28, 2022 (GLOBE NEWSWIRE) — Motus GI Holdings, Inc., (NASDAQ: MOTS)…
Jasper Therapeutics Announces Plans for Registrational Study of JSP191 in Older Patients with Myelodysplastic Syndromes or Acute Myeloid Leukemia Undergoing Hematopoietic Cell Transplantation after Type C FDA Meeting
Based on positive feedback provided by FDA on key clinical design details Jasper plans to…
Entera Bio to Report First Quarter 2022 Financial Results on May 12
BOSTON and JERUSALEM, April 28, 2022 (GLOBE NEWSWIRE) — Entera Bio Ltd. (NASDAQ: ENTX), a…
Madrigal Pharmaceuticals to Announce First Quarter 2022 Financial Results and Provide Clinical and Business Updates on May 9
CONSHOHOCKEN, Pa., April 28, 2022 (GLOBE NEWSWIRE) — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage…
PDS Biotechnology Announces Conference Call and Webcast for First Quarter 2022 Financial Results
FLORHAM PARK, N.J., April 28, 2022 (GLOBE NEWSWIRE) — PDS Biotechnology Corporation (Nasdaq: PDSB), a…
Immutep to Announce New TACTI-002 Data in an Oral Presentation at the ASCO 2022 Annual Meeting
SYDNEY, AUSTRALIA, April 28, 2022 (GLOBE NEWSWIRE) — Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or…
Selecta Biosciences to Host Conference Call and Webcast to Discuss First Quarter 2022 Financial Results and Provide Business Update
WATERTOWN, Mass., April 28, 2022 (GLOBE NEWSWIRE) — Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology…
Vaxxinity Completes Enrollment in Part B of UB-312 Phase 1 Clinical Trial for Parkinson’s Disease
Results from UB-312’s Part A first-in-human trials published in Movement Disorders DALLAS, April 28, 2022…
Cytek Biosciences Appoints Todd Garland Chief Commercial Officer
Industry Seasoned Executive Joins Cytek FREMONT, Calif., April 28, 2022 (GLOBE NEWSWIRE) — Cytek Biosciences,…
Checkpoint Therapeutics Announces Data Presentation of Pivotal Trial Results of Cosibelimab to be Presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
WALTHAM, Mass., April 28, 2022 (GLOBE NEWSWIRE) — Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a…
ProKidney Appoints Libbie Parker McKenzie, MD, FASN as Chief Medical Officer
WINSTON-SALEM, N.C., April 28, 2022 (GLOBE NEWSWIRE) — ProKidney LP (ProKidney), a leading clinical-stage cellular…
PROCEPT BioRobotics Corporation Announces Aetna and Independence Blue Cross Blue Shield Positive Coverage Decisions Regarding Aquablation Therapy for Men with Enlarged Prostates
REDWOOD CITY, Calif., April 28, 2022 (GLOBE NEWSWIRE) — PROCEPT® BioRobotics Corporation (Nasdaq: PRCT), a surgical…
Cellectis Publishes Two Articles in Nature Communications Providing Strong Preclinical Validation of UCART123 to Treat AML and BPDCN
Preclinical data demonstrates that UCART123 effectively eliminates AML with no major impact on normal hematopoietic progenitor…